Navigation Links
Bacterin International to Present at Noble Financial Capital Markets' Seventh Annual Equity Conference on May 16, 2011
Date:5/4/2011

BELGRADE, Mont., May 4, 2011 /PRNewswire/ -- Bacterin International Holdings, Inc. ("Bacterin") (NYSE Amex: BONE), a developer of revolutionary bone graft material, today announced that its chairman and CEO, Guy Cook, will present at SEVEN; Noble Financial Capital Markets' Seventh Annual Equity Conference at the Hard Rock Hotel in Hollywood, Florida, on Monday, May 16, 2011 at 4:00p.m. Eastern Time.

At the time of the presentation, a live audio and high-definition video webcast of Bacterin's presentation and a copy of the presentation materials will be available on the Company's website www.bacterin.com, or through the Noble Financial websites: www.noblefcm.com, or www.noble7.com. Bacterin recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access. You will require a Microsoft SilverLight viewer (a free download from the presentation link) to participate. The webcast and presentation will also archived on the Bacterin website for 90 days following the event.

About Bacterin International Holdings, Inc.

BACTERIN INTERNATIONAL HOLDINGS, INC. ("the "Company" or "Bacterin") develops, manufactures and markets biologics products to domestic and international markets.  Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold and promote bone and other tissue growth.  These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain with a facet joint stabilization, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.

Bacterin's Medical Device division develops anti-microbial coatings based upon proprietary coating technologies. Bacterin develops, employs, and licenses bioactive coatings for various medical device applications.  Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination.  Headquartered in Belgrade, Montana, Bacterin operates a 32,000 square foot, state-of-the-art, fully compliant and FDA registered facility, equipped with five "Class 100" clean rooms.  For further information please visit www.bacterin.com.

About Noble Financial

Noble Financial Capital Markets was established in 1984 and is an equity research driven, full-service, investment banking boutique focused on small-cap, emerging growth companies. The company has offices in New York, Boston, New Jersey, St Louis, and Boca Raton. In addition to non-deal road shows and sector-specific conferences throughout the year, Noble Financial hosts its large format annual equity conference in late spring featuring 120 – 150 presenting companies from across North America and total attendance of close to 600. For more information: www.noblefcm.com

Certain statements in this news release may constitute "forward-looking" statements within the meaning of section 21E of the Securities and Exchange Act of 1934.  The Company believes that its expectations, as expressed in these statements are based on reasonable assumptions regarding the risks and uncertainties inherent in achieving those expectations.  These statements are not, however, guarantees of future performance and actual results may differ materially.  Risk factors are listed in the most recent 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission.  


'/>"/>
SOURCE Bacterin International Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Bacterin International Secures $1.9 million in Private Placement
2. Bacterin International Updates Fourth Quarter and Full Year 2010 Financial Results
3. Bacterin International Signs LOI to Acquire Assets of Robinson MedSurg LLC
4. Bacterin International Holdings Secures $5,000,000 Credit Facility with Bridge Bank
5. Bacterin International Reconstitutes Its Board of Directors and Appoints Experienced Legal and Financial Professionals
6. Bacterin International Appoints Three New Members to Its Board of Directors
7. New U.S. Patent Issued to Dyadic International
8. Early Diagnosis and Treatment the Focus of International Dialogue on Primary Immunodeficiency Disease
9. Progress in the Development of Mechanical Circulatory Support Devices for Children to be Presented at International Heart and Lung Transplant Meeting
10. DNA Analyzer "Hello Truth" Unveiled During Innocence Network International Delegate Tour of DDC
11. Dyadic International to Present at Advanced Biofuels Leadership Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... ... May 20, 2016 , ... Korean researchers say Manumycin A ... offer a new way to treat the disease. Surviving Mesothelioma has just posted an ... Scientists from several Korean institutions based their mesothelioma study on the fact the Manumycin ...
(Date:5/19/2016)... , ... May 19, 2016 , ... Anton Paar USA, ... square foot office building is complete. The new structure adds a third office building ... Anton Paar USA purchased 2.4 acres of land, along with office space adjacent ...
(Date:5/19/2016)... NEW YORK , May 19, 2016 ... Biotech space will fully recover given the relentless pressures ... is for sure in the investors circle though - ... requires due-diligence. Ahead of today,s session, ActiveWallSt.com,s presents four ... PTLA ), Vitae Pharmaceuticals Inc. (NASDAQ: ...
(Date:5/19/2016)... , May 19, 2016 ... and (OTC PINK: RGBPP) announced today initiation of ... first cord blood based cancer immunotherapeutic product leveraging ... application, Regen described a generation of cord blood ... by gene silencing.  The product in development will ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):